Sarepta Therapeutics faces challenges as the FDA halts gene therapy trials for LGMD and revokes AAVrh74 platform designation.

Separately, the FDA on Friday informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, that is approved to treat a different type of muscular dystrophy and was ...

In light of recent patient deaths, the FDA has also revoked its platform designation for Sarepta’s AAVrh74 technology. The ...

New board members bring decades of experience in company building, corporate strategy, commercialization, and business development CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: ...

U.S. stock futures moved higher Monday morning as Wall Street entered a pivotal week defined by high-stakes earnings from megacap tech giants and growing uncertainty surrounding President Trump’s ...

Silicon Valley insider and former Intel employee James Cape said Ohio is well-positioned to become a technological ...

Stock futures ticked higher Monday premarket, kicking off a busy week packed with big tech earnings. Here are some of Monday's biggest stock movers: Biggest stock gainers Block (NYSE:XYZ) +9% – Shares ...